Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2017 07:30 ET | Source: Dermira, Inc.

Dermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab

- Dermira plans to develop and commercialize lebrikizumab, a monoclonal antibody targeting IL-13, for moderate-to-severe atopic dermatitis - Initiation of a Phase 2b clinical study is expected in...
August 07, 2017 16:05 ET | Source: Dermira, Inc.

Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update

sBLA for CIMZIA® (certolizumab pegol) submitted to FDASubmission of NDA for glycopyrronium tosylate on schedule for second half of 2017Guidance for Phase 3 olumacostat glasaretil topline results...
July 25, 2017 01:00 ET | Source: Dermira, Inc.

UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis

The regulatory submissions for this new indication seek to expand the use of CIMZIA for the treatment of patients with moderate-to-severe chronic plaque psoriasisData from three positive Phase 3...
June 26, 2017 07:30 ET | Source: Dermira, Inc.

Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition

MENLO PARK, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
June 06, 2017 07:30 ET | Source: Dermira, Inc.

Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations

MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
May 30, 2017 16:05 ET | Source: Dermira, Inc.

Dermira to Present at Jefferies 2017 Global Healthcare Conference

MENLO PARK, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
May 16, 2017 16:01 ET | Source: Dermira, Inc.

Dermira Announces Closing of 3.00% Convertible Senior Notes Offering

MENLO PARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the...
May 10, 2017 21:32 ET | Source: Dermira, Inc.

Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes

MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior...
May 09, 2017 16:01 ET | Source: Dermira, Inc.

Dermira Announces Proposed Offering of $250 Million of Convertible Senior Notes

MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today that it intends to offer, subject to market conditions and other factors, $250,000,000 aggregate...
May 08, 2017 16:08 ET | Source: Dermira, Inc.

Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update

-Submissions for CIMZIA® (certolizumab pegol) and glycopyrronium tosylate remain on schedule for later this year MENLO PARK, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right